



Lartruvo™ (olaratumab)

Last Review Date: July 25, 2018

Number: MG.MM.PH.55

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

Lartruvo (olaratumab) is a human platelet-derived growth factor-alpha (PDGFR- α) monoclonal antibody that blocks PDGF-AA and -BB ligand binding and prevents PDGF-AA, -BB, and -CC-induced receptor activation and downstream PDGFR- α pathway signaling. PDGFR- α is a receptor tyrosine kinase expressed on cells of mesenchymal origin; it has been detected on some tumor and stromal cells, including sarcomas. It's signaling results in cancer cell proliferation, metastasis, and maintenance of the tumor microenvironment

Lartruvo (olaratumab) is FDA approved in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.

Dosing

Max Units (per dose and over time):

- Soft tissue sarcoma: 200 billable units (2,000 mg) on day 1 and 8 of a 21 day cycle

Guideline

Lartruvo (olaratumab) may be considered medically necessary when all of the following criteria are met:

- The patient is 18 years of age or older; **AND**
- The patient has a diagnosis of soft tissue sarcoma which is of a histologic subtype appropriate for an anthracycline-containing regimen; **AND**

- The soft tissue sarcoma is not amendable to curative treatment with radiotherapy or surgery;
AND
- Lartruvo (olaratumab) will be given in combination with doxorubicin

Coverage for Lartruvo (olaratumab) may be renewed when all of the following criteria are met:

- Disease response; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: severe infusion related reactions, mucositis, lymphopenia, neutropenia, thrombocytopenia, etc.

Limitations/Exclusions

- Approval will be granted for 6 months, and may be renewed

Applicable Procedure Codes

J9371	Injection, olaratumab, 10 mg
-------	------------------------------

Applicable Diagnosis Codes

C47.0	Malignant neoplasm of peripheral nerves of head, face, and neck
C47.1	Malignant neoplasm of peripheral nerves of upper limb, including shoulder
C47.10	Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder
C47.11	Malignant neoplasm of peripheral nerves of right upper limb, including shoulder
C47.12	Malignant neoplasm of peripheral nerves of left upper limb, including shoulder
C47.2	Malignant neoplasm of peripheral nerves of lower limb, including hip
C47.20	Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip
C47.21	Malignant neoplasm of peripheral nerves of right lower limb, including hip
C47.22	Malignant neoplasm of peripheral nerves of left lower limb, including hip
C47.3	Malignant neoplasm of peripheral nerves of thorax
C47.4	Malignant neoplasm of peripheral nerves of abdomen
C47.5	Malignant neoplasm of peripheral nerves of pelvis
C47.6	Malignant neoplasm of peripheral nerves of trunk, unspecified
C47.8	Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system
C47.9	Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified
C48.0	Malignant neoplasm of retroperitoneum and peritoneum
C48.1	Malignant neoplasm of specified parts of peritoneum
C48.2	Malignant neoplasm of peritoneum, unspecified
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
C49.0	Malignant neoplasm of connective and soft tissue of head, face, and neck
C49.1	Malignant neoplasm of connective and soft tissue of upper limb, including shoulder
C49.10	Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder
C49.11	Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder
C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder
C49.20	Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip
C49.21	Malignant neoplasm of connective and soft tissue of right lower limb, including hip

C49.22	Malignant neoplasm of connective and soft tissue of left lower limb, including hip
C49.3	Malignant neoplasm of connective and soft tissue of thorax
C49.4	Malignant neoplasm of connective and soft tissue of abdomen
C49.5	Malignant neoplasm of connective and soft tissue of pelvis
C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue
C49.9	Malignant neoplasm of connective and soft tissue, unspecified
C54.0	Malignant neoplasm of isthmus uteri
C54.1	Malignant neoplasm of endometrium
C54.2	Malignant neoplasm of myometrium
C54.3	Malignant neoplasm of fundus uteri
C54.8	Malignant neoplasm of overlapping sites of corpus uteri
C54.9	Malignant neoplasm of corpus uteri, unspecified
C55	Malignant neoplasm of uterus, part unspecified

References

1. Lartruvo prescribing information. Eli Lilly and Company. Indianapolis, IN. 2016
2. Clinical Pharmacology Elsevier Gold Standard. 2016.
3. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, Co. 2016.
4. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium.2016.
5. AHFS Drug Information. American Society of Health-Systems Pharmacists. Bethesda, MD. 2016.

